

**CD86: A Novel Prognostic Marker in
Acute Lymphoblastic Leukemia
Patients**

Thesis

*Submitted for Partial Fulfillment of Master
Degree in Clinical Pathology*

By

Asmaa Mohamed Abdel Razek Saleh

M.B.B.Ch

Ain Shams University

Supervised by

Professor/ Mona Ahmed Wahba

Professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

Doctor/ Heba Mostafa El-Maraghy

Lecturer of Clinical Pathology

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿ قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا

﴿ إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم
الآية (32) سورة البقرة



Acknowledgment

First and above all my deepest gratitude and thanks to **ALLAH** for achieving any work in my life.

It is a great honor to express my deep gratitude and appreciation to **Professor/ Mona Ahmed Wahba;** Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University for her keen supervision, continuous guidance throughout the study, patience and support despite having many tasks.

I would like to express my sincere thanks and deep gratitude to **Doctor/ Heba Mostafa El-Maraghy;** Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her energetic follow up with constructive advice, all hearted support, scientific criticism and creative suggestions.

I would like also to thank **my Husband, my Family** and **my Friends** for their help and continuous encouragement.

Finally, a dedication to my lovely Son **Ahmed** and the soul of my **Grandparents.**

Asmaa Mohamed Abd El Razek

Contents

Contents	Page No.
List of Abbreviations	i
List of Tables	v
List of Figures	vii
Introduction	1
Aim of the work	4
Review of Literature:	
I – Chapter 1	5
II- Chapter 2	34
Subjects and methods	53
Results	62
Discussion	87
Summary	97
Recommendations	100
References	101
Arabic Summary	-

List of Abbreviations

μL	: Micro liter
ALL	: Acute lymphoblastic leukemia
AML	: Acute myeloid leukemia
APCs	: Antigen presenting cells
ARF	: ADP-ribosylation factor
AUC	: Area under the curve
B-ALL	: B-cell Acute lymphoblastic leukemia
BCP-ALL	: B-cell precursor ALL
BCR/ABL	: Breakpoint cluster region/Abelson
BFM	: Berlin-Frankfurt-Münster
BM	: Bone marrow
CALLA	: Common ALL antigen
CBC	: Complete blood count
CCG	: Children's Cancer Group
CD	: Cluster of differentiation
CHL	: Classic Hodgkin lymphoma
CLL	: Chronic lymphocytic leukemia
C-Myc	: Cellular myelocytoma gene
CNS	: Central nervous system
CR	: Complete remission
CSCs	: Cancer stem cells
CSF	: Cerebrospinal fluid
CTL	: Cytotoxic T- lymphocytes
CTLA-4	: Cytotoxic T-lymphocyte antigen 4
DCs	: Dendritic cells
DNA	: Deoxyribonucleic acid
EBF1	: Early B cell factor 1
EDTA	: Ethylene-diamine-tetra-acetic acid
EMI	: Extramedullary involvement
FAB	: French-american-british

List of Abbreviations

FCM	: Flow cytometry
FISH	: Fluorescence in situ hybridization
FITC	: Fluorescein isothiocyanate
FRET	: Forster resonance energy transfer
GPI	: Glycosyl phosphatidyl inositol
HA	: Hyaluronic acid
Hb	: Hemoglobin
HLA	: Human leucocyte antigen
HLA-DR	: Human leukocyte differentiation antigen
HS	: Highly significant
HSCs	: stem cells
iAMP21	: Intra-chromosomal amplification of the chromosome 21
ICAM-1	: Intercellular adhesion molecule-1
ICOS-L	: Inducible costimulator ligand
IgC	: Immunoglobulin constant
IgE	: Immunoglobulin type E
IgG	: Immunoglobulin type G
IGSF	: Immunoglobulin superfamily
IgV	: Immunoglobulin variable
IKZF1	: IKAROS family zinc finger
IL	: Interleukin
IPMs	: Immunophenotypic markers
IPT	: Immunophenotyping
IS	: Immunological synapse
kDa	: Kilodalton
LSCs	: Leukemic stem cells
mCD86	: Membranous CD86
MFI	: Mean florescence intensity
MHC	: Major histocompatibility complex
MLL	: Myeloid–lymphoid lineage
MM	: Multiple myeloma

List of Abbreviations

MoAbs	: Monoclonal antibodies
MPO	: Myelo-peroxidase
MRD	: Minimal residual disease
MS	: Multiple sclerosis
NCI	: National Cancer Institute
NK	: Natural Killer cell
NPV	: Negative predictive value
NS	: Non significant
p	: Short arm of chromosome
P	: Probability
PAX5	: Paired box 5
PB	: Peripheral blood
PBS	: Phosphate buffered saline
PCR	: Polymerase chain reaction
PD-L1	: Programmed cell death-1 ligand
PD-L2	: Programmed cell death-2 ligand
PE	: Phycoerythrin
PHF6	: PHD finger protein 6
PLT	: Platelets
PMNs	: Polymorphonuclear cells
POG	: Pediatric Oncology Group
PPV	: Positive predictive value
q	: Long arm of chromosome
RNA	: Ribonucleic acid
ROC	: Receiver operating characteristic
RT-PCR	: Reverse transcriptase polymerase chain reaction
RUNX1	: Runt related transcription factor 1
S	: Significant
sCD44	: Serum levels of CD44
sCD86	: Serum levels of CD86
SD	: Standard deviation
Sig	: Significance

List of Abbreviations

SLE	: Systemic lupus erythematosis
t	: Translocation
T-ALL	: T-cell acute lymphoblastic leukemia
TCR	: T-cell receptor
TCR	: T cell receptor
TdT	: Terminal deoxynucleotidyl transferase
Teff	: Effector T cells
TEL-AML1	: Tel-acute myeloid leukemia
Th1	: T helper type 1
Th2	: T helper type 2
TIL	: Tumor infiltrating lymphocytes
TLC	: Total leukocytic count
TNFR	: Tumor necrosis factor receptor
TNFRSF	: Tumor necrosis factor superfamily
Treg	: Regulatory T cell
VISTA	: V-domain immunoglobulin suppressor of T cell activation
WBC	: White blood cell
WHO	: World health organization
WT1	: Wilms tumor 1
X²	: Chi- square test

List of Tables

<i>Table No.</i>	<i>Subject</i>	<i>Page No.</i>
Table (1)	Prognostic factors in childhood ALL	7
Table (2)	Prognostic factors in adults ALL	8
Table (3)	Chromosomal locations of B7- family genes	38
Table (4)	Characteristics of studied ALL patients	68
Table (5)	Laboratory data of the studied ALL patients	70
Table (6)	Comparison between control group and patients' group regarding CD86 expression percentage and MFI	71
Table (7)	The relationship between CD86 expression, demographic & clinical data among the ALL patients	72
Table (8)	Correlation between CD86 expression and laboratory data of the studied ALL patients	73
Table (9)	Association between CD86 expression and immunophenotyping of ALL patients	74
Table (10)	Association between MFI and demographic, clinical data & immunophenotyping among the ALL patients	75

List of Tables

<i>Table No.</i>	<i>Subject</i>	<i>Page No.</i>
Table (11)	Correlation between MFI and laboratory data of the studied ALL patients	76
Table (12)	The association between CD86% expression and mean fluorescence intensity (MFI) with patient outcome	77
Table (13)	Standard prognostic factors in comparison with outcome in studied ALL patients	78
Table (14)	Best cut-off value of CD86% and MFI for the prediction of poor prognosis	79
Table (15)	Raw data of all studied patients	85
Table (16)	Immunophenotyping of all studied patients	86

List of Figures

<i>Figure No.</i>	<i>Subject</i>	<i>Page No.</i>
Figure (1)	Proposed Risk-Classification System for pediatric ALL	22
Figure (2)	Risk assessment for adult acute lymphoblastic leukemia (ALL)	23
Figure (3)	T-cell activation and targeted therapy using specific immune checkpoint inhibitors	36
Figure (4)	Structure of the receptor-binding domain of human B7-2	40
Figure (5)	Dynamics of B7 ligand recognition at effector and Treg IS	42
Figure (6)	Co-stimulatory interactions between helper T cells and acute myeloid leukemia cells	47
Figure (7)	Pie chart showing patients' outcome	79
Figure (8)	Comparison between control and patients as regards mean values of CD86 %	80
Figure (9)	Comparison between control and patients as regards mean values of CD86 mean fluorescence intensity (MFI)	80
Figure (10)	Histogram showing the relation between patient outcome and CD86 %	81

List of Figures

<i>Figure No.</i>	<i>Subject</i>	<i>Page No.</i>
Figure (11)	Histogram showing the relation between patient outcome and CD86 mean fluorescence intensity (MFI)	81
Figure (12)	Receiver operating characteristic curve (ROC) curve showing the best cut-off value for CD86% and MFI	82
Figure (13)	Flowcytometric analysis represents a case of ALL. Left histogram showing gated blast cells (73.1%) and right histogram showing high expression of CD86 (90.1%)	82
Figure (14)	Flowcytometric analysis represents a case with low CD86 expression. Left histogram shows gated blasts (89.2%), right histogram shows CD86 expression (23.4%), MFI: 1.00	83
Figure (15)	Flowcytometric analysis represents a control with negative CD86 expression. Left histogram shows gated blasts (5.0%), right histogram shows CD86 expression (4.9%)	84

Introduction

Leukemia is a hematopoietic malignancy that results from the clonal proliferation of bone marrow cells with impaired differentiation, regulation, and cell death. The acute leukemias arise from neoplastic transformation of hematopoietic stem cells or progenitors with aberrant differentiation and proliferation (**Gowda and Dovat, 2013**).

Acute lymphocytic leukemia (ALL) is the most common hematological malignancy in childhood and accounts for about 20% of acute leukemia in adults (**Liew et al., 2012**).

On the basis of ontogenic classification, ALL is divided into T-lineage ALL and B-lineage ALL. B-lineage ALL is characterized by the expression of the B-cell markers CD19, CD22 and CD79a (**Pui et al., 2008**).

T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive malignancy of thymocytes and corresponds to a heterogeneous group of leukemia arrested at various stages of lymphoid development. T-ALL constitutes 15% of all childhood ALL and 25% of adult ALL; approximately 30% of patients relapse within the first year of treatment and the outcome is usually death (**Pui et al., 2004-a**).

Leukemogenesis is a multistep process that requires the accumulation of alterations in a hematopoietic progenitor cell at multiple stages. The leukemic stem cell (LSC) hypothesis postulates that leukemia are hierarchically organized and leukemic stem cells have the capacity to self-renew, give rise to more differentiated progeny and maintain the leukemia long-term (**Magee et al., 2012**).

CD86 is a member of B7 family, which consists of cell-surface proteins that regulate costimulatory or coinhibitory signals by binding to their ligands (**Greaves and Gribben, 2013**).

Recognition of CD86 ligand by co-stimulatory CD28 and co-inhibitory CTLA-4 receptors plays an important role in influencing immune responses by proliferation and suppression of effector T cells respectively (**Postow et al., 2015**).

CD86 is expressed on the surface of antigen presenting cells (APCs) as monocytes and dendritic cells (DCs) (**Lim et al., 2012**). Its expression was found to be associated with many hematological malignancies such as acute myeloid leukemia (AML) and it was reported as a marker of poor prognosis in it (**Barrett and Le Blanc,**

2010). The expression of it in ALL cells is variable but it is mostly associated with poor prognosis in those patients **(Mansour et al., 2014).**

Some of the most recent therapeutic developments for acute leukemia depend on the involvement of costimulatory pathways and molecules including CD86 **(Couzin-Frankel, 2013).**